CSPC Innovation Pharmaceutical Co., Ltd. (SHE:300765)
China · Delayed Price · Currency is CNY 43.52
+1.12 (2.64%)
Sep 14, 2026, 3:04 PM CST
SHE:300765 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 59,046 | 50,231 | 37,029 | 42,873 | 9,767 | 8,376 | |
Market Cap Growth | -24.29% | 35.65% | -13.63% | 338.97% | 16.61% | 6.59% |
Enterprise Value | 55,710 | 49,475 | 36,671 | 39,717 | 7,864 | 6,725 |
Last Close Price | 42.40 | 36.07 | 26.58 | 30.25 | 7.19 | 6.92 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 58.15 | - | 689.22 | 98.69 | 13.45 | 21.30 |
Forward PE | 39.80 | 102.68 | 51.60 | 50.21 | 12.60 | - |
PS Ratio | 13.58 | 23.28 | 18.69 | 16.89 | 3.72 | 4.53 |
PB Ratio | 13.55 | 17.97 | 8.24 | 7.82 | 2.48 | 2.54 |
P/TBV Ratio | 15.87 | 20.52 | 10.56 | 8.49 | 2.51 | 2.59 |
P/FCF Ratio | 28.31 | - | - | 306.85 | 18.54 | 86.64 |
P/OCF Ratio | 21.61 | - | - | 59.45 | 15.24 | 28.68 |
PEG Ratio | - | 5.70 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 12.81 | 22.93 | 18.51 | 15.64 | 2.99 | 3.64 |
EV/EBITDA Ratio | 40.75 | - | - | 128.72 | 9.60 | 13.34 |
EV/EBIT Ratio | 49.25 | - | - | 258.24 | 10.53 | 15.46 |
EV/FCF Ratio | 26.71 | - | - | 284.26 | 14.93 | 69.57 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.06 | 0.00 | 0 | 0 | 0.01 | 0 |
Debt / EBITDA Ratio | 0.18 | - | - | 0.01 | 0.02 | 0.00 |
Debt / FCF Ratio | 0.12 | - | - | 0.01 | 0.04 | 0.01 |
Net Debt / Equity Ratio | -0.86 | -0.49 | -0.38 | -0.69 | -0.55 | -0.50 |
Net Debt / EBITDA Ratio | -2.75 | 3.37 | 28.14 | -12.21 | -2.66 | -3.29 |
Net Debt / FCF Ratio | -1.80 | 1.78 | 0.99 | -26.97 | -4.13 | -17.14 |
Asset Turnover | 0.59 | 0.35 | 0.29 | 0.42 | 0.63 | 0.55 |
Inventory Turnover | 3.41 | 2.98 | 3.71 | 5.98 | 5.97 | 5.59 |
Quick Ratio | 1.22 | 0.76 | 1.58 | 2.28 | 5.00 | 5.31 |
Current Ratio | 1.42 | 1.05 | 1.95 | 2.42 | 5.48 | 6.09 |
Return on Equity (ROE) | 26.10% | -16.71% | -6.08% | 2.67% | 20.07% | 13.12% |
Return on Assets (ROA) | 9.51% | -6.36% | -2.56% | 1.59% | 11.22% | 8.12% |
Return on Invested Capital (ROIC) | 94.40% | -29.56% | -12.26% | 4.23% | 37.41% | 24.93% |
Return on Capital Employed (ROCE) | 23.40% | -17.50% | -6.00% | 2.80% | 18.70% | 13.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.73% | -0.48% | 0.14% | 1.01% | 7.44% | 4.70% |
FCF Yield | 3.53% | -1.52% | -4.63% | 0.33% | 5.39% | 1.15% |
Dividend Yield | 0.04% | - | 0.07% | 0.88% | 0.97% | 1.00% |
Payout Ratio | 0.94% | - | 696.42% | 22.52% | 11.30% | 10.68% |
Buyback Yield / Dilution | -1.38% | 0.44% | -0.16% | -4.50% | 0.02% | -13.53% |
Total Shareholder Return | -1.34% | 0.44% | -0.08% | -3.62% | 0.98% | -12.53% |